DRUG
Bivalirudin (thrombin specific anticoagulant)
Percutaneous Coronary Intervention
Status
Withdrawn
Phase
Not applicable
Enrollment
0
Locations
0
Results
Not posted
Publications
0
Study summary
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime different from unfractionated heparin in monotherapy. About thirty catheterization laboratories will co-operate in this activity. The long term outcome of patients will be taken into consideration. The availability of these data will allow for a better understanding of the therapeutic needs in this area.
Interventions
DRUG
Percutaneous Coronary Intervention
Timeline
First posted
Apr 24, 2006
Study start
Mar 2006
Primary completion
Not reported
Study completion
Feb 2008
Results posted
Not reported
Registry updated
May 7, 2012
Outcomes
Not reported in the indexed record.
Not reported in the indexed record.
Eligibility
Inclusion Criteria : * Medical condition or disease to be studied: age \> 18 years. * Patients are candidates for a PCI with a planned anticoagulation regime other than unfractionated heparin in monotherapy. Taking into consideration the national and international guidelines for this area and the registered indications of the drugs currently used for this purpose it is predicted that the patients will probably receive one of the following: * unfractionated heparin as an intravenous (IV) bolus followed by IV bolus + infusion of a GPI (abciximab, tirofiban or eptifibatide); or * bivalirudin as an IV bolus followed by IV infusion, as per the pertinent Summary of Product Characteristics (SPCs). * Having provided an informed consent (to anonymous data treatment). * A planned anticoagulation regime means that any candidate patient should be identified on the basis of pre-procedural factors and requested to give his/her consent before the PCI is initiated. Patients receiving bail-out GPI for intraprocedural complications should NOT be considered for the inclusion. However, a pre-included patient could receive a bail-out GPI if deemed necessary. * The allocation of any individual patient to the category of "high risk" elective PCI will be made independently and autonomously by the caring physician. However, it is recommended to consider the suitability of patients on the basis of these indicative elements: * age \> 75 years. * known diabetes mellitus (type I or type II). * known renal insufficiency, i.e. serum creatinine \> 1.8 mg or glomerular filtration rate (GFR) \> 60 ml/min (calculated with the Cockroft formula). * multivessel or complex procedure. * planned stent on a bifurcation. * planned stent \> 6 cm long. * PCI on a degenerated venous bypass: in this particular case a distal protection device should always be used. * non ST elevation acute coronary syndrome with a PCI planned later than 72 hours after the diagnosis without clinical instability (= "cooled" non ST elevation acute coronary syndrome). This type of patient is considered to be essentially stable and his/her level of risk can be comparable to the risk of patients who are candidates for elective PCI with additional risk factors as listed above. Exclusion Criteria: * There will be no specific exclusion criteria other than those listed in the Summary of Product Characteristics of every individual agent.
Study locations
No country data reported. Showing up to 24 locations stored in the fast local snapshot.
No study locations reported.
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Duke University · Coronavirus Infection (COVID-19) · Pulmonary Arterial Hypertension
Not applicable
Recruiting
5,000
2026-07
Sydney Local Health District · Extracorporeal Membrane Oxygenation Complication
Phase 2
Recruiting
80
2026-05
Xiaotong Hou · Extracorporeal Membrane Oxygenation Complication
Not applicable
Recruiting
154
2026-04
Shenyang Northern Hospital · Percutaneous Coronary Intervention · High Bleeding Risk
Phase 4
Not yet recruiting
5,270
2026-02
Stanford University · Heart Failure · Cardiogenic Shock
Phase 2
Recruiting
50
2026-01
NYU Langone Health · Coronary Microvascular Disease · Ischemic Heart Disease
Not applicable
Active, not recruiting
206
2025-11
Shenyang Northern Hospital · ST Elevation Myocardial Infarction
Not applicable
Completed
6,016
2025-08
Peking University First Hospital · Coronary Microvascular Dysfunction
Phase 4
Recruiting
70
2025-08
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.